- Home
- MRT vs ZNTL Comparison
MRT vs ZNTL Comparison
Compare MRT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRT | ZNTL |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.5M | 156.7M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MRT | ZNTL |
|---|---|---|
| Price | $2.08 | $2.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.00 | ★ $6.60 |
| AVG Volume (30 Days) | 19.7K | ★ 665.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.87 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,425,000.00 |
| Revenue This Year | $84.47 | N/A |
| Revenue Next Year | $94.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.97 | $1.01 |
| 52 Week High | $3.70 | $3.95 |
Technical Indicators
Market Signals| Indicator | MRT | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 54.37 |
| Support Level | $1.98 | $1.29 |
| Resistance Level | $2.15 | $3.95 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 23.44 | 50.00 |
Price Performance
Historical ComparisonAbout MRT Marti Technologies Inc.
Marti Technologies Inc is a mobility app, offering multiple transportation services to its riders. Marti operates a ride-hailing service that matches riders with car, motorcycle, and taxi drivers, and operates a large fleet of rental e-mopeds, e-bikes, and e-scooters. All of Marti's offerings are serviced by proprietary software systems and IoT infrastructure.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.